Back to Search
Start Over
The Citrullinated and MMP-degraded Vimentin Biomarker (VICM) Predicts Early Response to Anti-TNF alpha Treatment in Crohn's Disease
- Source :
- Journal of clinical gastroenterology, 55(1), 59-66. LIPPINCOTT WILLIAMS & WILKINS, Mortensen, J H, van Haaften, W T, Karsdal, M A, Bay-Jensen, A-C, Olinga, P, Grønbæk, H, Hvas, C L, Manon-Jensen, T, Dijkstra, G & Dige, A 2021, ' The Citrullinated and MMP-degraded Vimentin Biomarker (VICM) Predicts Early Response to Anti-TNFα Treatment in Crohn's Disease ', Journal of Clinical Gastroenterology, vol. 55, no. 1, pp. 59-66 . https://doi.org/10.1097/MCG.0000000000001341
- Publication Year :
- 2021
-
Abstract
- BACKGROUND: In Crohn's disease (CD), 10% to 40% of patients do not respond to anti-tumor necrosis factor-α (TNFα) treatment. Currently, there are no biomarkers with adequate sensitivity to separate responders from nonresponders at an early stage.AIM: The aim of this study was to investigated whether early changes in the VICM (citrullinated and matrix metalloproteinase-degraded vimentin) biomarker were associated with response to anti-TNFα treatment in patients with CD.METHODS: Serum VICM levels were measured by ELISA in 2 independent cohorts of CD patients (n=42) treated with anti-TNFα (infliximab or adalimumab). Response was determined by achieving clinical remission (Harvey Bradshaw IndexRESULTS: Compared with baseline, VICM serum levels were reduced by anti-TNFα in the infliximab cohort (week 6 and 14) and in the adalimumab cohort (week 8). VICM was lower in the responders compared with the nonresponders [infliximab: week 6, PCONCLUSIONS: The VICM biomarker was time dependently reduced in CD patients responding to anti-TNFα treatment. We suggest that VICM may be used as a marker for monitoring early response to anti-TNFα in patients with CD.
- Subjects :
- EXPRESSION
medicine.medical_specialty
Crohn’
MATRIX METALLOPROTEINASES
PATHOGENESIS
DIAGNOSIS
Gastroenterology
s disease
03 medical and health sciences
0302 clinical medicine
Crohn Disease
Internal medicine
citrullinated vimentin
EVIDENCE-BASED CONSENSUS
INFLIXIMAB
Adalimumab
MANAGEMENT
Medicine
Humans
Vimentin
MACROPHAGES
serological biomarkers
Crohn's disease
business.industry
Tumor Necrosis Factor-alpha
Area under the curve
Odds ratio
anti-TNF
medicine.disease
Infliximab
Treatment Outcome
030220 oncology & carcinogenesis
prediction of response
Cohort
Biomarker (medicine)
030211 gastroenterology & hepatology
Tumor necrosis factor alpha
business
INHIBITORS
Biomarkers
medicine.drug
INFLAMMATORY-BOWEL-DISEASE
Subjects
Details
- Language :
- English
- ISSN :
- 01920790
- Database :
- OpenAIRE
- Journal :
- Journal of clinical gastroenterology, 55(1), 59-66. LIPPINCOTT WILLIAMS & WILKINS, Mortensen, J H, van Haaften, W T, Karsdal, M A, Bay-Jensen, A-C, Olinga, P, Grønbæk, H, Hvas, C L, Manon-Jensen, T, Dijkstra, G & Dige, A 2021, ' The Citrullinated and MMP-degraded Vimentin Biomarker (VICM) Predicts Early Response to Anti-TNFα Treatment in Crohn's Disease ', Journal of Clinical Gastroenterology, vol. 55, no. 1, pp. 59-66 . https://doi.org/10.1097/MCG.0000000000001341
- Accession number :
- edsair.doi.dedup.....2dfd1a24f7473d279a675f4c25fc13ea